Why Braveheart Bio, Inc.’s (BRVE) Stock Is Down 5.12%
As of Thursday, September 03, Braveheart Bio, Inc.’s BRVE share price has dipped by 5.12%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Commentary & Analysis
Financial Summary
| Share Statistics | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,729.4 | $674.0 | 51% |
|
| Shares Out (Mil) | 30.1 | 43.9 | 37% |
|
| Institutional Ownership | na | 84.7% | na |
|
| Float (Mil) | na | 47.3 | na |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 261 | 293 | 49% |
|
| Price Change (52-week) |
na | 68.8% | na |
|
| Growth | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.8% | na |
|
| Net Income (5yr) | na | (1.5%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($80) | ($11) | 13% |
|
| EPS (TTM) | ($2.632) | ($0.700) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($7) | 22% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 13% |
|
| Enterprise Value (Q1) (Mil) | $1,835 | $575 | 48% |
|
| Valuation | BRVE | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.80 | na |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.5% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (196.0%) | (24.6%) | 2% |
|
| ROE | 204.7% | (21.4%) | 98% |
|
| Liabilities to Assets | 12.7% | 32.2% | 8% |
|
| F-Score | 1 | 3 | na |
|
Braveheart Bio, Inc. did not pass any screens on 9/2/2026.
